Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval

This cross-sectional study evaluates patient exposure to oncology drugs withdrawn from the US Food and Drug Administration (FDA) Accelerated Approval program.

Detalles Bibliográficos
Autores principales: Parikh, Ravi B., Hubbard, Rebecca A., Wang, Erkuan, Royce, Trevor J., Cohen, Aaron B., Clark, Amy S., Mamtani, Ronac
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951100/
https://www.ncbi.nlm.nih.gov/pubmed/36821118
http://dx.doi.org/10.1001/jamaoncol.2022.7770
_version_ 1784893315881107456
author Parikh, Ravi B.
Hubbard, Rebecca A.
Wang, Erkuan
Royce, Trevor J.
Cohen, Aaron B.
Clark, Amy S.
Mamtani, Ronac
author_facet Parikh, Ravi B.
Hubbard, Rebecca A.
Wang, Erkuan
Royce, Trevor J.
Cohen, Aaron B.
Clark, Amy S.
Mamtani, Ronac
author_sort Parikh, Ravi B.
collection PubMed
description This cross-sectional study evaluates patient exposure to oncology drugs withdrawn from the US Food and Drug Administration (FDA) Accelerated Approval program.
format Online
Article
Text
id pubmed-9951100
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-99511002023-02-25 Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval Parikh, Ravi B. Hubbard, Rebecca A. Wang, Erkuan Royce, Trevor J. Cohen, Aaron B. Clark, Amy S. Mamtani, Ronac JAMA Oncol Research Letter This cross-sectional study evaluates patient exposure to oncology drugs withdrawn from the US Food and Drug Administration (FDA) Accelerated Approval program. American Medical Association 2023-02-23 2023-04 /pmc/articles/PMC9951100/ /pubmed/36821118 http://dx.doi.org/10.1001/jamaoncol.2022.7770 Text en Copyright 2023 Parikh RB et al. JAMA Oncology. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Research Letter
Parikh, Ravi B.
Hubbard, Rebecca A.
Wang, Erkuan
Royce, Trevor J.
Cohen, Aaron B.
Clark, Amy S.
Mamtani, Ronac
Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval
title Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval
title_full Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval
title_fullStr Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval
title_full_unstemmed Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval
title_short Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval
title_sort exposure to us cancer drugs with lack of confirmed benefit after us food and drug administration accelerated approval
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951100/
https://www.ncbi.nlm.nih.gov/pubmed/36821118
http://dx.doi.org/10.1001/jamaoncol.2022.7770
work_keys_str_mv AT parikhravib exposuretouscancerdrugswithlackofconfirmedbenefitafterusfoodanddrugadministrationacceleratedapproval
AT hubbardrebeccaa exposuretouscancerdrugswithlackofconfirmedbenefitafterusfoodanddrugadministrationacceleratedapproval
AT wangerkuan exposuretouscancerdrugswithlackofconfirmedbenefitafterusfoodanddrugadministrationacceleratedapproval
AT roycetrevorj exposuretouscancerdrugswithlackofconfirmedbenefitafterusfoodanddrugadministrationacceleratedapproval
AT cohenaaronb exposuretouscancerdrugswithlackofconfirmedbenefitafterusfoodanddrugadministrationacceleratedapproval
AT clarkamys exposuretouscancerdrugswithlackofconfirmedbenefitafterusfoodanddrugadministrationacceleratedapproval
AT mamtanironac exposuretouscancerdrugswithlackofconfirmedbenefitafterusfoodanddrugadministrationacceleratedapproval

Ejemplares similares